Anavex Life Sciences Corp (AVXL)

[Anshu2]

Worth repeating.

1. AD P3 with SPA and US-based.


2. No more endpoint change. (Do we have 100% certainty on what the EXCELLENCE endpoints are? Well, what
CM says doesn’t really count …)

I hope the upcoming PD p3 trial initiation and Excellence readout are the turning point. No more p2b/3, just well-designed AD p3 with SPA and US-based. No more endpoint change, just clean and significant Rett results.